Characterization of novel MPS1 inhibitors with preclinical anticancer activity.
Jemaà, M
Characterization of novel MPS1 inhibitors with preclinical anticancer activity. [electronic resource] - Cell death and differentiation Nov 2013 - 1532-45 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
1476-5403
10.1038/cdd.2013.105 doi
Animals
Antineoplastic Combined Chemotherapy Protocols--pharmacology
Apoptosis--drug effects
Cell Cycle--drug effects
Cell Cycle Proteins--antagonists & inhibitors
Drug Synergism
Female
HeLa Cells
Humans
Mice
Mice, Nude
Neoplasms--drug therapy
Paclitaxel--administration & dosage
Protein Kinase Inhibitors--administration & dosage
Protein Serine-Threonine Kinases--antagonists & inhibitors
Protein-Tyrosine Kinases--antagonists & inhibitors
Random Allocation
Transfection
Xenograft Model Antitumor Assays
Characterization of novel MPS1 inhibitors with preclinical anticancer activity. [electronic resource] - Cell death and differentiation Nov 2013 - 1532-45 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
1476-5403
10.1038/cdd.2013.105 doi
Animals
Antineoplastic Combined Chemotherapy Protocols--pharmacology
Apoptosis--drug effects
Cell Cycle--drug effects
Cell Cycle Proteins--antagonists & inhibitors
Drug Synergism
Female
HeLa Cells
Humans
Mice
Mice, Nude
Neoplasms--drug therapy
Paclitaxel--administration & dosage
Protein Kinase Inhibitors--administration & dosage
Protein Serine-Threonine Kinases--antagonists & inhibitors
Protein-Tyrosine Kinases--antagonists & inhibitors
Random Allocation
Transfection
Xenograft Model Antitumor Assays